期刊文献+

沙利度胺近年临床新用中出现的不良反应 被引量:11

Adverse reactions occurring in new clinical uses of thalidomide in recent years
原文传递
导出
摘要 20世纪60年代初因发现沙利度胺有致畸作用将其撤出市场。但对沙利度胺的研究并未因此停止。60年代中期发现沙利度胺能有效治疗麻风结节红斑而再次引入临床。此后,沙利度胺用于治疗多种其他疾病。然而,在治疗过程中出现一些严重不良反应,如末梢神经病、血栓形成、血细胞减少以及肝毒性。了解这些不良反应无疑将有助于沙利度胺的安全应用。 Thalidomide was withdrawn from the market in the early 1960s after it was discovered that it produced teratogenic effects. Despite its withdrawal from market, thalidomide research did not discontinued. In the mid-1960s, it was found that thalidomide was an effective treatment for erythema nedosum leprosum; therefore, it was reintroduced to clinical practice. Since then, thalidomide has been used in several other diseases. However, serious adverse reactions, such as peripheral neuropathy, thrombosis, cytopenia, and hapatoxicity, occurred in thalidomide treatment. Understanding these adverse reactions no doubt is helpful to safe use of thalidomide.
作者 施桂英
出处 《药物不良反应杂志》 2007年第5期332-334,共3页 Adverse Drug Reactions Journal
关键词 沙利度胺 末梢神经病 血栓形成 thalidomide peripheral neuropathy thrombosis
  • 相关文献

参考文献18

  • 1Matthews SJ, McCoy C. Thalidomide: a review of approved and investigational uses[ J]. Clin Ther, 2003, 25 ( 2 ) : 342 -395.
  • 2Hall VC, El-Aghary RA, Bouwhuis S, et al. Dermatologic side effects of thalidomide in patients with multiple myeloma[J]. J Am Acad Dermatol, 2003, 48(4) :548- 552.
  • 3Clark TE, Edom N, Larson J, et al. Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing [ J ]. Drug Saf, 2001, 24 (2) : 87- 117.
  • 4Bastuji-Garin S, Ochonisky S, Bouche P, et al. Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients [ J ]. J Invest Dermatol, 2002, 119 (5) :987-1020.
  • 5Tosi P, Zamagni E, Cellini C, et al. Neurological toxicity of long-term ( > lyr) thalidomide therapy in patients with multiple myeloma [ J ]. Eur J naematol, 2005, 74 ( 3 ) : 212-216.
  • 6Mileshkin L, Stark R, Day B, et al. Development of neuropathy in patients with myeloma treated with thalidomide : patterns of occurrence and the role of electrophysiologic monitoring[ J ]. J Clin Oncol, 2006, 24 ( 27 ) : 4507- 4514.
  • 7Briani C, Zara G, Rondinone R, et al. Positive and negative effects of thalidomide on refractory cutaneous lupus erythematosus [ J ]. Autoimmunity, 2005, 38 ( 7 ) : 549- 555.
  • 8Coelho A, Souto MI, Cardoso CR, et al. Long-term thalidomide use in refractory cutaneous lesions of lupus erythematosus : a 65 series of Brazilian patients [ J ]. Lupus, 2005, 14(6) :434-439.
  • 9Sharma NL, Sharma VC, Mahajan VK, et al. Thalidomide: An experience in therapeutic outcome and adverse reactions[J]. J Dermatolog Treat, 2007, 21:1-6.
  • 10Zangari M, Barlogie B, Cavallo F, et al. Effect on survival of treatment-associated venous thromboemblism in newly diagnosed multiple myeloma patients [J]. Blood Coagul Fibrinolysis, 2007, 18 (7):595-598.

同被引文献63

引证文献11

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部